Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20191247Keywords:
Angiogenesis, Epithelial ovarian cancer, Ovarian cancer, Vascular endothelial growth factorAbstract
Epithelial ovarian cancer (EOC) is one of the most lethal gynaecologic malignancies with an increasing incidence worldwide; there is an increasing need for the identification of novel prognostic biomarkers in EOC patients. Given the key role of angiogenesis and growth factors in the biology of tumorigenesis, vascular endothelial growth factor (VEGF) is considered a milestone in the process of ovarian cancer progression and invasiveness. Authors aimed in the present study to evaluate the relevance of serum level of VEGF with clinicopathological parameters in patients with EOC. VEGF is reported to be correlated with variable parameters in EOC patients including International Federation of Gynecology and Obstetrics (FIGO) classification, lymph nodal involvement and ascites formation. In the following review, authors discussed these correlations and distinguished the possible future role of VEGF as a promising prognostic biomarker for EOC patients.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J National Cancer Institute. 2002;94(1):32-8.
Ranjbar R, Nejatollahi F, Nedaei Ahmadi AS, Hafezi H, Safaie A. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in patients with serous ovarian carcinoma and their clinical significance. Iranian J Cancer Prev. 2015;8(4):e3428.
Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer research. 1984;44(8):3584-92.
Dimova I, Popivanov G, Djonov V. Angiogenesis in cancer-general pathways and their therapeutic implications. J BUON. 2014;19(1):15-21.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.
Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol. 2012;127(1):210-6.
Leppanen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci U S A. 2010;107(6):2425-30.
Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-9.
Mukherjee S, Pal M, Mukhopadhyay S, Das I, Hazra R, Ghosh S, et al. vegf expression to support targeted therapy in ovarian surface epithelial neoplasms. JCDR. 2017;11(4):EC43-6.
Premalata CS, Umadevi K, Shobha K, Anurekha M, Krishnamoorthy L. Expression of VEGF-A in epithelial ovarian cancer: correlation with morphologic types, grade and clinical stage. Gulf J Oncol. 2016;1(21):49-54.
Bankhead CR, Collins C, Stokes‐Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115(8):1008-14.
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303.
Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. Post Reproductive Health. 2017;23(4):183-98.
Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-6.
Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol. 2014;38(9):1173-81.
Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-95.
McGee SF, Lanigan F, Gilligan E, Groner B. Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression. EMBO Reports. 2006;7(11):1084-8.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology. 2005;17(5):548-58.
Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008;68(4):1100-9.
Matkar PN, Ariyagunarajah R, Leong-Poi H, Singh KK. Friends turned foes: angiogenic growth factors beyond angiogenesis. Biomolecules. 2017;7(4).
Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clinical Cancer Research: J Am Assoc Cancer Res. 2003;9(15):5721-8.
Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol: J Am Soc Clin Oncol. 2008;26(1):76-82.
Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol: J the Am Soc Clin Oncol. 2009;27(18):3020-6.
Vlasova MA, Moshkovskii SA, Safarova MP, Makarov OV, Archakov AI. Molecular diagnostics of ovarian cancer using proteome techniques. Biomeditsinskaia Khimiia. 2005;51(4):367-83.
Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011;4(3):365-74.
Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012;127(1):75-82.
Watanabe Y, Satou T, Nakai H, Etoh T, Dote K, Fujinami N, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol. 2010;116(5):1027-34.
Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Nat Cancer Inst. 2005;97(8):560-6.
Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lecuru F. Complications of lymphadenectomy for gynecologic cancer. Europ J Surg Oncol: J Europ Soc Surg Oncol Brit Assoc Surg Oncol. 2013;39(1):81-6.
Duyndam MC, Hilhorst MC, Schlüper HM, Verheul HM, Van Diest PJ, Kraal G, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol. 2002;160(2):537-48.
Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res: J American Assoc Can Res. 2008;14(10):3030-5.
Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer: J Int Gynecol Cancer Soc. 2009;19 Suppl 2:S18-20.
Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Brit J Cancer. 2000;83(2):196-203.
Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43.
Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918-31.
Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol. 2001;98(1):85-90.
Ayhan A, Gultekin M, Taskiran C, Celik NY, Usubutun A, Kucukali T, et al. Lymphatic metastasis in epithelial ovarian carcinoma with respect to clinicopathological variables. Gynecol Oncol. 2005;97(2):400-4.
Siddiqui GK, Elmasry K, Wong AT, Perrett C, Morris R, Crow JC, et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Europ J Gynaecol Oncol. 2010;31(2):156-9.
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 1998;83(12):2528-33.
